tiprankstipranks
Trending News
More News >
Vitalhub (TSE:VHI)
TSX:VHI

Vitalhub (VHI) AI Stock Analysis

Compare
163 Followers

Top Page

TS

Vitalhub

(TSX:VHI)

76Outperform
Vitalhub's notable strengths include robust revenue growth, strategic acquisitions, and a solid financial position with no debt. However, operational efficiency challenges and a high P/E ratio pose risks. The company is well-positioned for future growth, but potential short-term margin impacts from acquisitions should be monitored.

Vitalhub (VHI) vs. S&P 500 (SPY)

Vitalhub Business Overview & Revenue Model

Company DescriptionVitalhub Corp., together with its subsidiaries, provides technology solutions for health and human service providers in Canada, the United States, the United Kingdom, Australia, Western Asia, and internationally. Its solutions include electronic healthcare record, case management, care coordination, patient flow and operational visibility, and mobile apps. The company was incorporated in 2010 and is based in Toronto, Canada.
How the Company Makes MoneyVitalhub generates revenue through the sale and licensing of its software solutions to healthcare institutions. The company offers its products on a subscription basis, providing ongoing support and updates as part of its service model. Additionally, Vitalhub engages in strategic partnerships with healthcare providers and organizations to expand its market reach and integrate its technology into existing systems. These collaborations contribute to the company's growth by increasing its customer base and enhancing its product offerings. Revenue is also supplemented by professional services, which include implementation, training, and consulting services tailored to meet the specific needs of their clients.

Vitalhub Financial Statement Overview

Summary
Vitalhub exhibits a robust financial profile with strong revenue and cash flow growth, high gross margins, and minimal leverage. The slight decline in net profit margin is a minor concern, but overall financial stability is strong.
Income Statement
85
Very Positive
Vitalhub shows strong revenue growth with a TTM revenue increase of 17.3% compared to the previous year. Gross profit margin remains high at 77.0% for TTM, indicating efficient cost management. Net profit margin has decreased slightly in TTM to 5.1%, suggesting some pressure on net income. However, EBIT and EBITDA margins are healthy at 11.4% and 21.0%, respectively, reflecting good operational performance.
Balance Sheet
90
Very Positive
The company maintains a robust balance sheet with a low debt-to-equity ratio of 0.0028, indicating minimal leverage. The return on equity is 2.5% for TTM, which is stable. A high equity ratio of 72.2% suggests strong financial stability and a solid asset base. The company’s cash position is strong, providing flexibility for future growth.
Cash Flow
88
Very Positive
Vitalhub demonstrates solid cash flow performance with a 5.1% growth in free cash flow in TTM. Operating cash flow to net income ratio is strong at 6.9, suggesting efficient cash conversion. The free cash flow to net income ratio is high at 6.7, indicating effective capital expenditure management and strong cash generation relative to net income.
Breakdown
TTMDec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Income StatementTotal Revenue
61.61M52.51M39.97M24.66M13.79M10.23M
Gross Profit
47.45M42.81M32.94M19.43M10.29M7.47M
EBIT
7.04M6.86M4.66M324.33K-369.31K-567.70K
EBITDA
12.95M10.38M5.25M1.12M148.12K649.36K
Net Income Common Stockholders
3.15M4.55M1.21M-1.95M-2.17M-625.53K
Balance SheetCash, Cash Equivalents and Short-Term Investments
33.32M33.48M17.45M16.39M23.39M2.00M
Total Assets
129.64M118.78M106.19M72.77M64.08M24.14M
Total Debt
521.65K541.09K882.20K792.51K987.89K2.48M
Net Debt
-32.79M-32.94M-16.57M-15.60M-22.40M481.05K
Total Liabilities
45.04M36.88M30.79M17.95M13.77M7.46M
Stockholders Equity
84.60M81.91M75.40M54.82M50.31M16.68M
Cash FlowFree Cash Flow
21.21M20.18M5.83M-309.58K294.35K-186.55K
Operating Cash Flow
21.70M20.47M6.12M-49.97K405.14K-107.69K
Investing Cash Flow
-9.76M-4.15M-21.84M-10.06M-9.37M-2.86M
Financing Cash Flow
38.65M-287.89K16.40M3.17M30.37M2.22M

Vitalhub Technical Analysis

Technical Analysis Sentiment
Negative
Last Price9.35
Price Trends
50DMA
10.25
Negative
100DMA
10.71
Negative
200DMA
9.59
Negative
Market Momentum
MACD
-0.10
Negative
RSI
55.34
Neutral
STOCH
86.68
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VHI, the sentiment is Negative. The current price of 9.35 is below the 20-day moving average (MA) of 9.36, below the 50-day MA of 10.25, and below the 200-day MA of 9.59, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 55.34 is Neutral, neither overbought nor oversold. The STOCH value of 86.68 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VHI.

Vitalhub Peers Comparison

Overall Rating
UnderperformOutperform
Sector (48)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
C$1.03B13.689.25%36.56%
TSVHI
76
Outperform
C$518.32M153.352.65%30.64%-39.92%
48
Neutral
$6.35B1.19-46.87%2.63%17.16%1.34%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:VHI
Vitalhub
9.35
3.15
50.81%
TSE:WELL
WELL Health Technologies Corp
4.18
0.42
11.17%

Vitalhub Earnings Call Summary

Earnings Call Date: Mar 27, 2025 | % Change Since: -3.21% | Next Earnings Date: May 8, 2025
Earnings Call Sentiment Positive
The earnings call highlighted strong revenue growth, successful acquisitions, and a solid financial position with no debt. However, there were concerns about a slight decrease in services revenue and potential short-term impacts on margins due to recent acquisitions. Overall, the positive aspects, including the strategic acquisitions and revenue growth, outweighed the lowlights.
Highlights
Strong Revenue Growth
Total revenue for Q3 2024 was $16.5 million, reflecting a 25% increase over the prior year period.
Increase in Recurring Revenue
Annual recurring revenue at the end of Q3 2024 was $53.5 million, up 25% from the previous year.
Successful Acquisitions
Completed acquisitions of MedCurrent and Strata Health, adding a combined $14.6 million to ARR, with Strata Health being the largest transaction in the company's history.
Cash Reserves and No Debt
As of September 30, 2024, the company reported cash on hand of $81.4 million and no debt.
High Adjusted EBITDA Margin
The adjusted EBITDA for Q3 2024 was $4.6 million, with a margin of 28%.
Lowlights
Decrease in Services Revenue
Services, hardware, and other revenue decreased by 1% year-over-year due to slower deployment during the summer quarter.
Potential Margin Impact from Acquisitions
The integration of recent acquisitions might lead to a temporary reset in EBITDA margins over the next few quarters.
Seasonal Challenges in Services
Q3 is typically a light quarter for services due to staff and customer holidays during the summer months.
Company Guidance
During the Q3 2024 earnings call for VitalHub, the company provided guidance highlighting significant growth metrics and strategic developments. Total revenue for the quarter was reported at $16.5 million, marking a 25% increase compared to the same period last year. Recurring revenue, a key focus for the company, reached $53.5 million annually, reflecting a 25% year-over-year growth. The gross margin stood at 81%, slightly down from 82% the previous year. Net income before taxes was $2.4 million, while adjusted EBITDA was $4.6 million, leading to an impressive adjusted EBITDA margin of 28%. The company successfully closed two acquisitions post-quarter: MedCurrent, adding $2.3 million in annual recurring revenue (ARR), and Strata Health, contributing an additional $12.3 million in ARR, bringing the pro forma ARR to $68 million. With over $50 million in cash and no debt, VitalHub is well-positioned to maintain its growth trajectory while integrating these acquisitions.

Vitalhub Corporate Events

M&A TransactionsBusiness Operations and StrategyFinancial Disclosures
VitalHub Reports Strong Financial Growth in 2024 with Strategic Acquisitions
Positive
Mar 27, 2025

VitalHub Corp. reported a significant increase in its financial performance for the year 2024, with annual recurring revenue rising by 59% to $71.1 million and total revenue up by 51% to $20.6 million. The company achieved a 27% year-over-year growth in adjusted EBITDA, reaching $5.0 million, driven by both organic growth and strategic acquisitions. VitalHub’s CEO, Dan Matlow, highlighted the company’s momentum in platform functionality and reputational awareness, with a balanced growth across its EHR suite in Canada and patient flow solutions in the UK. The company completed four acquisitions in 2024, adding $17.9 million in acquisition ARR, and is focused on integrating these acquisitions to enhance revenue growth and operational efficiency. With a strong cash balance of approximately $90 million, VitalHub is well-positioned for continued mergers and acquisitions activity in 2025.

Financial Disclosures
VitalHub Schedules Q4 2024 Financial Results Release and Conference Call
Neutral
Mar 17, 2025

VitalHub Corp. has announced the release of its Q4 2024 financial results, scheduled for March 27, 2025, with a subsequent conference call on March 28, 2025. This announcement reflects VitalHub’s ongoing commitment to transparency and engagement with stakeholders, potentially impacting its market positioning and investor relations.

VitalHub Raises $34.5 Million for Healthcare Expansion
Jan 9, 2025

VitalHub has successfully closed a $34.5 million public offering, utilizing a bought deal led by Cormark Securities Inc. The proceeds from this offering will support the company’s growth initiatives, specifically targeting acquisitions in the healthcare industry. This strategic move is expected to enhance VitalHub’s market position by providing synergistic opportunities, aligning with its expansion strategy.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.